Target Audience
- Readers who want to gain a systematic understanding of the Chan Zuckerberg Initiative (CZI), including its origins, evolution, and current activities.
- Researchers, entrepreneurs, and professionals interested in AI, life sciences, healthcare innovation, and private investment in scientific research.
- Individuals interested in new organizational and funding models for foundations, research institutions, and startups, as well as the challenges associated with these models.
Executive Summary
- The Chan Zuckerberg Initiative (CZI) is a major philanthropic organization established in 2015 by Meta founder Mark Zuckerberg and pediatrician Priscilla Chan.
- Initially focused on a broad range of societal challenges, including education, healthcare, science, inequality, immigration, and criminal justice reform, CZI has increasingly concentrated its resources on the intersection of AI and life sciences.
- In November 2025, CZI announced that Biohub, its biomedical research organization, would become the central focus of its future philanthropic activities.
- Unlike traditional grant-making foundations, CZI combines research funding with the direct development of research facilities, AI models, scientific software, and data infrastructure.
- Its major challenges include translating large-scale research investments into meaningful medical advances, managing the consequences of strategic changes, ensuring transparency and accountability, and maintaining long-term organizational sustainability.
1. What Is the Chan Zuckerberg Initiative (CZI)?
The Chan Zuckerberg Initiative (CZI) is a major U.S.-based philanthropic organization founded in 2015 by Mark Zuckerberg, the founder of Meta, and his wife, Priscilla Chan, a pediatrician.
At its founding, CZI aimed to address a broad range of societal challenges, including education, healthcare, scientific research, inequality, immigration, criminal justice reform, and community development.
However, its strategy has evolved significantly over the past decade.
As of 2026, CZI has transformed into a research-driven philanthropic organization primarily focused on understanding, preventing, and treating diseases through the integration of artificial intelligence and life sciences.
A particularly significant milestone occurred on November 6, 2025, when its founders announced that Biohub, a biomedical research organization, would become the primary focus of their future philanthropic efforts, with the majority of resources directed toward this initiative. [2][6]
1.1 Key Facts About CZI
The following table summarizes CZI's scale and current strategic direction.
| Item | Details |
|---|---|
| Founded | 2015 |
| Founders | Priscilla Chan and Mark Zuckerberg |
| Original philanthropic commitment | A pledge to devote 99% of their Facebook shares to philanthropic purposes over their lifetimes |
| Cumulative grants | Approximately $7.22 billion |
| Cumulative venture investments | Approximately $300 million |
| Current primary focus | AI, life sciences, and Biohub |
| Future scientific investment strategy | A plan to double investment in science over the next decade |
The cumulative grant and venture investment figures are based on publicly reported amounts on CZI's official website since 2015. They do not represent CZI's total assets.
Likewise, the proposed increase in scientific investment represents a future funding strategy rather than guaranteed expenditure. [1][2][6]
1.2 Five Key Characteristics of CZI
Several characteristics distinguish CZI from traditional philanthropic foundations.
- A distinctive organizational structure. Rather than operating solely as a conventional charitable foundation, CZI is organized around a limited liability company (LLC), allowing it to combine grants, investments, and technology development with considerable flexibility.
- Activities extending beyond grant-making. In addition to funding external researchers, CZI directly develops research facilities, AI models, scientific software, and data infrastructure.
- Increasing concentration on science and AI. Since 2025, CZI has clearly positioned Biohub as its central initiative, emphasizing long-term development of foundational technologies for life sciences.
- Continued education initiatives alongside reduced social policy funding. CZI continues to support education, particularly through Learning Commons, while discontinuing or reducing funding for social advocacy related to immigration reform, racial equity, and other policy issues.
- The challenge of demonstrating long-term impact. CZI must demonstrate that substantial investments can ultimately produce meaningful medical progress while addressing transparency, organizational sustainability, and the effects of shifting priorities on previously supported organizations.
2. CZI's History: From Its Founding to the Present
CZI's evolution can be understood through four major phases.
| Period | Strategic Phase | Main Characteristics |
|---|---|---|
| 2015–2017 | Founding and expansion of its vision | Established to address a broad range of societal challenges |
| 2018–2022 | Program expansion and evaluation | Expanded grants and technology development across science, education, and social policy |
| 2023–2024 | Strategic shift toward scientific research | Expanded Biohub and increased emphasis on AI and biology |
| 2025–2026 | Transition to a Biohub-centered organization | Prioritized AI-driven life sciences and organizational restructuring |
2.1 Phase One: 2015–2017 — Establishment as a Broad Social Impact Organization
In December 2015, following the birth of their first daughter, Max, Mark Zuckerberg and Priscilla Chan announced their intention to devote 99% of their Facebook shares to philanthropic purposes over their lifetimes.
At the time, these shares were valued at approximately $45 billion.
Importantly, this announcement did not mean that the entire $45 billion was immediately transferred to a charitable foundation. Rather, it represented a long-term commitment to directing their wealth toward philanthropic objectives.
CZI initially focused on four broad priorities:
- Personalized learning
- Curing diseases
- Connecting people around the world
- Building strong communities
Through these initiatives, its founders articulated a vision of creating a better world for future generations. [1][7]
In 2016, CZI established the Chan Zuckerberg Biohub in collaboration with universities in the San Francisco Bay Area.
This initiative became the foundation of CZI's present-day research strategy, combining fundamental biomedical research with advanced technology development.
2.2 Phase Two: 2018–2022 — Expanding Across Multiple Social Challenges
During this period, CZI organized its work around three major areas:
- Science
- Education
- Justice & Opportunity
In education, CZI invested in educational technology, learning research, and school support.
In science, it provided grants to researchers while supporting scientific infrastructure and technological development.
In social policy, it pursued initiatives related to criminal justice reform, housing, immigration, and equity.
In 2021, CZI also announced plans to expand its Biohub network, moving from a single research center toward a network of large-scale research institutions. [1]
During this phase, CZI operated as a broad philanthropic organization supporting multiple social challenges simultaneously.
2.3 Phase Three: 2023–2024 — A Strategic Shift Toward Science and AI
In 2023, CZI launched Biohub Chicago.
The new research center was established to support interdisciplinary research on inflammation and biological measurement technologies through collaboration among multiple universities.
At the same time, CZI advanced its "Virtual Cell" initiative, which aims to develop AI models capable of predicting the states and behaviors of biological cells.
This represented an important shift in its scientific priorities.
Rather than concentrating primarily on research grants, CZI increasingly emphasized the development of data resources, AI models, and computational infrastructure.
Organizational changes also accompanied this transition.
In 2023, CZI reduced staffing in its education division, and in 2024, it moved toward greater integration of its science-related organizations.
These developments helped establish the foundation for its subsequent transition toward a Biohub-centered organizational structure. [1][4]
2.4 Phase Four: 2025–2026 — Transformation Into a Biohub-Centered Research Organization
In February 2025, CZI formally explained that it had been gradually discontinuing grants related to social advocacy as part of its increasing focus on scientific research. [3]
In June 2025, Priscilla Chan further emphasized the organization's commitment to biology and artificial intelligence.
Then, on November 6, 2025, CZI's founders announced that Biohub would become the central focus of their future philanthropic activities. [2]
In January 2026, reports indicated that approximately 70 employees would be affected by staff reductions associated with this strategic transition.
At the same time, CZI reportedly continued hiring specialists in AI, data science, and computational biology.
These developments illustrate a transformation not only in CZI's priorities but also in the nature of the organization itself.
The multi-sector philanthropic organization established in 2015 differs substantially from the science-centered research organization operating in 2026, both in strategic priorities and resource allocation.
3. CZI's Distinctive Organizational Model
One of CZI's defining characteristics is that it does not function merely as a philanthropic grant provider.
Instead, it combines the capabilities of a research institution, investor, technology company, and charitable foundation to address complex societal challenges.
3.1 An Organizational Structure Centered on an LLC
Traditional charitable foundations in the United States receive certain tax benefits but operate under restrictions regarding the use of funds, disclosure requirements, and other activities.
CZI, by contrast, is organized around an LLC and incorporates several different legal entities and philanthropic funding mechanisms.
| Organization or Mechanism | Primary Function |
|---|---|
| Chan Zuckerberg Initiative, LLC | Organizational management, strategic support, funding, investments, and related activities |
| Chan Zuckerberg Initiative Foundation | Supports charitable activities as a 501(c)(3) organization |
| Donor-Advised Fund (DAF) | Manages philanthropic funds and facilitates grants |
| Chan Zuckerberg Initiative Advocacy | A 501(c)(4) organization focused on social advocacy |
This structure allows CZI to combine charitable grants with investments in for-profit companies and direct technology development.
However, the LLC itself is not subject to all the same restrictions and disclosure requirements that apply to traditional nonprofit foundations.
This flexibility is both an advantage of the model and a source of questions regarding transparency and accountability. [7]
3.2 Moving Beyond Grant-Making to Direct Research and Development
Traditional grant-making philanthropy typically supports universities, researchers, nonprofit organizations, and other external institutions by providing funding for their activities.
CZI's research-driven approach is different.
It directly establishes research facilities and technical teams, collaborating with external researchers to develop shared scientific infrastructure.
In addition to funding external institutions, CZI brings together scientists, AI engineers, and data scientists to create tools that address bottlenecks in scientific research.
Its current approach emphasizes the integration of five essential components.
| Component | Description |
|---|---|
| Data | Large-scale cellular and biological datasets |
| Compute | Large-scale computational infrastructure for training AI models |
| Models | AI models designed to predict biological systems |
| Labs | Research facilities for experimentation and validation |
| Talent | Interdisciplinary teams of biologists, physicians, AI researchers, and engineers |
In 2025, CZI also announced an expanded collaboration with NVIDIA to strengthen the data, modeling, and evaluation infrastructure supporting its Virtual Cell Platform. [4]
CZI is therefore evolving beyond its role as a research funder into an organization that directly builds technological infrastructure for the broader scientific community.
3.3 Investing in Long-Term, High-Risk Research
CZI's vision of a future in which all diseases can be cured, prevented, or managed is not a goal that can be achieved in the short term.
Consequently, Biohub pursues major scientific challenges that may require 10 to 15 years of sustained research.
Its approach emphasizes interdisciplinary projects that individual universities or companies may find difficult to undertake independently.
This model allows CZI to invest in long-term scientific infrastructure without being constrained solely by conventional grant periods or annual performance metrics. [2][4]
The ability to sustain ambitious, long-horizon research is one of CZI's most distinctive strengths.
4. Current Strategic Priorities
CZI's current activities can be classified according to their strategic importance.
| Area | Current Position | Main Activities |
|---|---|---|
| AI and Life Sciences | Highest-priority core initiative | Biohub, Virtual Cell, disease research |
| Education | Continuing major initiative | Learning Commons, AI infrastructure for education |
| Community Support | Continuing regional support | Local nonprofits, community development, and quality-of-life initiatives |
| Venture Investments | Complementary social impact mechanism | Investments in life sciences and education companies |
| Social Policy and Advocacy | Previous major funding programs reduced or discontinued | Former initiatives involving immigration reform, criminal justice reform, and racial equity |
[1][3]
4.1 Highest Priority: AI and Life Sciences Through Biohub
Biohub is a biomedical research organization dedicated to understanding the mechanisms underlying diseases and developing technologies that can support their prevention, diagnosis, and treatment.
Its research strategy currently centers on four major "Grand Challenges." [4]
1. Virtual Cell: Building AI Models of Biological Cells
The Virtual Cell initiative aims to develop AI models capable of predicting cellular behavior by integrating information about gene expression, proteins, environmental conditions, and other biological factors.
In the future, these models could help researchers predict the effects of drugs or genetic interventions before performing physical experiments.
2. Advanced Imaging: Developing New Biological Imaging Technologies
This initiative focuses on developing microscopy and image analysis technologies capable of observing living cells and tissues at high resolution.
Its goal is to enable scientists to understand biological changes at previously inaccessible levels of precision and across new spatial and temporal scales.
3. Inflammation: Measuring and Controlling Inflammatory Processes
Inflammation is involved in many diseases.
Biohub aims to develop sensors and measurement technologies capable of monitoring inflammatory changes within living tissues.
The long-term objective is to better understand inflammation in real time and develop ways to control it.
4. Immune Engineering: Harnessing the Immune System
This initiative combines AI and cellular engineering to analyze and modify immune cells.
Its goal is to develop technologies that contribute to early disease detection, prevention, and treatment.
4.2 Biohub's Research Centers
Biohub collaborates with multiple U.S. universities, with different research centers focusing on distinct scientific challenges.
| Research Center | Established or Launched | Main Research Areas |
|---|---|---|
| Biohub San Francisco | 2016 | Cell biology, measurement technologies, imaging, and technology development |
| Biohub Chicago | 2023 | Inflammation, biological measurement, and tissue sensors |
| Biohub New York | 2023 | Immune cell analysis and engineering, disease detection |
Biohub Chicago collaborates with:
- University of Chicago
- Northwestern University
- University of Illinois Urbana-Champaign
Biohub New York collaborates with:
- Columbia University
- Rockefeller University
- Yale University
Biohub connects these research centers with AI researchers and computational infrastructure.
Since 2025, CZI has strengthened efforts to integrate these activities into a unified research organization. [2][4]
4.3 The Scale of Biohub's Investment
According to a November 2025 report by the Associated Press, Biohub's planned annual operating budget was approximately $1 billion.
The report also described plans to double the approximately $4 billion invested in basic science over the previous decade during the next ten years. [2][6]
These figures demonstrate the scale of CZI's long-term commitment to AI and life sciences.
However, they represent investment plans rather than guaranteed future expenditures.
4.4 Education: Learning Commons
In education, Learning Commons plays an important role.
Launched in 2025 as an initiative taking over CZI's education activities, Learning Commons aims to translate research in learning science into AI and data infrastructure that educators and educational software developers can use. [5]
Previously, CZI's education initiatives covered a broad range of activities, including research grants, school support, and educational technology development.
Its current emphasis is more focused on shared infrastructure, including:
- Structured data connecting curriculum content, educational standards, and learning science
- Systems for evaluating the quality of AI-generated instructional materials and assignments
- Shared software infrastructure for educational technology developers
- Collaborative design with teachers and schools to ensure practical relevance
In 2026, efforts to make an AI platform available to developers also progressed.
This shift does not mean that CZI has completely withdrawn from education.
Rather, its focus has moved from broadly supporting individual educational initiatives toward building shared technological infrastructure for AI-enabled education. [5]
4.5 Community Support
CZI continues to provide support to local communities.
Its community initiatives are primarily concentrated in regions where its founders live or maintain strong connections.
Major areas include:
- San Mateo County, California
- Kauai, Hawaii
CZI has supported local nonprofit organizations, community initiatives, and efforts related to living conditions and community development.
However, as of 2026, Biohub has clearly become the highest priority in CZI's allocation of resources. [1]
4.6 Venture Investments
In addition to philanthropic grants, CZI has also pursued venture investments.
Through CZI Ventures, the organization has invested in companies addressing social challenges, particularly in education and life sciences.
Unlike conventional donations, these investments aim to combine business growth with measurable social impact.
According to figures published on CZI's official website, cumulative venture investments total approximately $300 million.
This combination of grants, direct research and development, and venture investing is another distinctive feature of CZI's organizational model. [1]
5. Major Challenges Facing CZI
Despite its substantial financial resources and research capabilities, CZI faces several important challenges.
The following analysis distinguishes between developments confirmed through official announcements or reporting and broader strategic issues that warrant consideration.
| Challenge | Importance (Assessment in This Article) | Key Questions |
|---|---|---|
| Translating research into real-world impact | High | Can major investments lead to meaningful advances in diagnosis and treatment? |
| Impact of strategic changes on funding recipients | High | What are the consequences of withdrawing from previously supported areas? |
| Governance and transparency | High | How are founder-led decisions made and disclosed? |
| Reliability and quality of biological AI | High | How can accuracy, reproducibility, and safety be ensured? |
| Organizational restructuring and talent acquisition | Medium–High | How can CZI integrate its operations and attract specialized talent? |
| Long-term financial and operational sustainability | Medium–High | How can expensive research facilities and computational infrastructure be maintained? |
The importance ratings in this table represent an analytical assessment for this article and are not official CZI evaluations.
5.1 Challenge One: Translating Scientific Advances Into Medical Outcomes
CZI's central strategy is to accelerate basic life sciences research through AI models and large-scale biological data.
However, there is a substantial gap between developing AI models and improving patient health.
The process generally requires several stages.
- Collecting large-scale biological datasets.
- Developing AI models of cells and immune systems.
- Validating models through laboratory experiments.
- Understanding underlying disease mechanisms.
- Developing diagnostic and therapeutic approaches and evaluating them clinically.
- Ultimately improving patient health outcomes.
In 2025, progress was made in virtual cell research and the release of research infrastructure for scientists.
However, such progress does not automatically translate into the immediate availability of new medical treatments. [4]
Future evaluations should therefore consider not only model performance but also independent reproducibility, improvements in experimental efficiency, and the translation of research findings into clinical applications.
The key distinction is between successfully developing AI technologies and demonstrating their contribution to disease prevention and treatment.
5.2 Challenge Two: The Impact of Reduced Support for Social Policy and Education
CZI previously supported several social policy areas, including:
- Criminal justice reform
- Immigration reform
- Racial equity
- Housing-related initiatives
However, in February 2025, CZI officially explained that it had been gradually discontinuing social advocacy grants as it concentrated more resources on scientific research. [3]
Although education and community programs continued into 2026, Biohub became the organization's primary focus.
This change can be evaluated from two perspectives.
A Positive Interpretation
Concentrating resources in areas of comparative strength may enable CZI to achieve greater impact through sustained investment in scientific infrastructure, AI, and specialized research talent.
A Critical Interpretation
For organizations that previously depended on substantial philanthropic support, changes in founders' priorities can create uncertainty regarding future funding and operational continuity.
Inside Philanthropy, a publication specializing in the philanthropic sector, reported disappointment among some organizations and observers regarding CZI's retreat from social advocacy.
The central issue is therefore not simply whether strategic concentration is appropriate, but also how CZI manages the transition for organizations and communities that previously received its support.
5.3 Challenge Three: Governance and Transparency in the LLC Model
CZI's LLC-centered organizational structure offers advantages, including flexibility in combining investments, advocacy, and other activities.
At the same time, its founders retain substantial influence, and the organization operates under a different regulatory and disclosure framework from conventional nonprofit foundations.
Since its founding in 2015, discussions have emerged regarding taxation, transparency, and the influence of private wealth on public priorities.
Legal scholarship has also noted that philanthropic LLCs can expand the capital available for addressing social challenges while potentially increasing the decision-making power of wealthy individuals. [7]
However, choosing an LLC structure does not itself demonstrate improper tax avoidance.
Moreover, entities within CZI that qualify as 501(c)(3) charitable organizations remain subject to their respective legal requirements.
Three governance questions are particularly important.
- To what extent are the financial flows associated with grants, investments, and research operations publicly disclosed?
- Who determines research priorities and evaluates the outcomes of major scientific projects?
- Who can access and use the resulting AI models, datasets, and intellectual property, and under what conditions?
5.4 Challenge Four: Reliability and Governance of AI and Biological Data
Biohub is moving toward integrating diverse types of biological data, including cellular, genetic, molecular, and imaging datasets.
Large-scale biological AI research generally faces several technical challenges.
- Biases within datasets
- Differences in experimental conditions
- Limitations in AI model prediction accuracy
- Difficulties in independent validation
When human-derived biological data are involved, additional considerations include consent, privacy, and data usage conditions.
These concerns should not be interpreted as evidence of misconduct specific to CZI.
Rather, they represent research and operational risks that any organization developing large-scale biological AI infrastructure must address.
5.5 Challenge Five: Organizational Restructuring and Sustainability
In January 2026, reports indicated that CZI would reduce its workforce by approximately 70 employees.
At the same time, the organization reportedly continued recruiting specialists in AI, data science, and computational biology.
These changes reflect the challenges associated with transforming an organization that previously managed broad social policy and education programs into a specialized research and development institution.
Several issues will be particularly important.
- Integrating the different professional cultures of scientists, AI engineers, physicians, and operational managers
- Continuously attracting highly specialized research talent
- Securing sustained funding for long-term scientific projects
- Maintaining expensive research facilities and computational infrastructure
Biohub's future success will depend not only on its scientific strategy but also on its ability to address these organizational challenges.
6. Future Outlook and Key Developments to Watch
Several indicators will be useful for evaluating CZI's progress over the next three to five years.
| Focus Area | Key Indicators to Monitor |
|---|---|
| Virtual Cell | Predictive accuracy, experimental validation by external researchers, broader adoption |
| Biohub Research Outcomes | Progress beyond publications and research tools toward diagnostic and therapeutic applications |
| AI Infrastructure | Computing capacity, dataset quality, and conditions for external access |
| Academic and Industry Collaboration | Partnerships with external research institutions, pharmaceutical companies, and biotechnology firms |
| Learning Commons | Adoption by education developers and measured outcomes in schools |
| Organizational Management | Continuity of research funding, talent acquisition, and transparency |
These indicators are not predictions of future success.
Rather, they provide a framework for evaluating whether CZI's strategy is producing meaningful results.
6.1 Research Progress in Virtual Cell
Virtual Cell is among the most important initiatives within CZI's AI and life sciences strategy.
In the coming years, attention should focus not only on improvements in AI model accuracy but also on their practical usefulness in biological research.
Independent experimental validation by external scientists will be especially important.
6.2 Biohub's Scientific Results and Medical Applications
Evaluating Biohub's progress will require looking beyond the number of published papers or developed research tools.
A critical question is whether its scientific advances can eventually lead to new diagnostic and therapeutic technologies.
Because basic research often takes many years to translate into clinical applications, it will be important to distinguish short-term scientific progress from long-term contributions to healthcare.
6.3 AI Infrastructure and Collaboration With Universities and Companies
One of Biohub's distinctive features is its effort to develop shared infrastructure that enables researchers to access data, computational resources, and AI models.
Future evaluations should consider not only computational capacity and data quality but also the conditions under which external researchers can access these resources.
Another important development will be how Biohub's collaborations evolve, including partnerships with universities, independent research organizations, pharmaceutical companies, and biotechnology firms.
6.4 Education and Organizational Management
For Learning Commons, important indicators will include adoption of its AI infrastructure by educational technology developers and evidence of effectiveness in actual school environments.
At the organizational level, the continuity of research funding, recruitment of specialized personnel, and transparency of decision-making will remain important considerations.
6.5 CZI in One Sentence
CZI can be described as an organization that uses philanthropic capital to build long-term scientific and technological infrastructure.
Rather than merely distributing research grants, it establishes research organizations, develops AI models and datasets, invests in scientific facilities, and aims to make these resources available to a broader research community.
If this model succeeds, it could demonstrate a new form of philanthropy in which long-term private capital creates shared infrastructure for fundamental scientific research, accelerating discoveries across universities and companies.
However, realizing this potential will require addressing several challenges beyond technological development, including organizational dependence on founders' priorities, public accountability, data governance, and responsibilities toward former funding recipients.
7. Overall Assessment
CZI can be evaluated across several dimensions, including financial resources, technological capabilities, strategic clarity, organizational distinctiveness, scientific outcomes, and social risks.
| Evaluation Dimension | Assessment in This Article |
|---|---|
| Financial Resources | Substantial resources enable long-term investment in major research facilities and AI infrastructure |
| Technological Capabilities | Combines scientific talent, AI expertise, and computational resources across biology and artificial intelligence |
| Strategic Clarity | Greater focus than in 2015, with Biohub now positioned as the highest priority |
| Organizational Distinctiveness | Integrates philanthropic grants, direct research and development, and impact-oriented venture investments |
| Scientific Outcomes | Significant progress in technological infrastructure, while long-term contributions to disease treatment remain under evaluation |
| Organizational and Social Risks | Challenges include strategic shifts, transparency, and effects on previously supported organizations |
The most significant transformation in CZI's history is its evolution from an organization distributing resources across a wide range of societal challenges into one that directly develops scientific technologies and research infrastructure.
When CZI was established in 2015, its priorities included education, science, inequality, immigration, criminal justice reform, and other social issues.
Over time, through program expansion and evaluation, it increasingly concentrated resources on science and artificial intelligence.
By 2025, the transition toward a research-driven organization centered on Biohub had become explicit.
This change demonstrates that CZI is seeking to become more than a provider of scientific funding.
It is positioning itself as a developer of shared infrastructure for AI-powered life sciences research.
The central question for evaluating CZI's future success is whether its investments in AI and biology will produce practical research infrastructure that external scientists can use and, ultimately, contribute to advances in disease prevention, diagnosis, and treatment.
At the same time, it will be important to monitor the consequences of changing organizational priorities for previous funding recipients, the transparency of its LLC-centered organizational model, and the conditions under which scientific results are shared and used.
CZI represents a distinctive philanthropic model that mobilizes substantial private capital to advance long-term scientific research.
Its activities offer important insights not only for AI and life sciences but also for broader discussions about research funding models, collaboration between universities and private organizations, and organizational structures designed to address complex societal challenges.
References
[1] Chan Zuckerberg Initiative, “Annual Letters (2015–2025),” Chan Zuckerberg Initiative. https://chanzuckerberg.com/about/annual-letter/
[2] Chan Zuckerberg Biohub, “An Update From Our Founders,” 2025. https://biohub.org/blog/founders-update-ai-powered-biology/
[3] Chan Zuckerberg Initiative, “Refining Our Focus: Updates on CZI’s Science Work and Policies,” 2025. https://chanzuckerberg.com/blog/refining-our-focus-updates-on-czis-science-work-and-policies/
[4] Chan Zuckerberg Biohub, “Frontier AI Biology Initiative,” 2025. https://biohub.org/blog/frontier-ai-biology-initiative/
[5] Learning Commons, “About Us,” Learning Commons. https://learningcommons.org/about-us/
[6] Associated Press, “Report on the Chan Zuckerberg Initiative’s Strategic Shift Toward Scientific Research,” Associated Press, 2025. https://apnews.com/article/87c24eb349abcce8abec132b8538d7b0
[7] Florida Law Review, “Disruptive Philanthropy,” Florida Law Review, Vol. 70, No. 5, 2018. https://scholarship.law.ufl.edu/flr/vol70/iss5/1/